409 related articles for article (PubMed ID: 25982275)
1. Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.
Pazarentzos E; Giannikopoulos P; Hrustanovic G; St John J; Olivas VR; Gubens MA; Balassanian R; Weissman J; Polkinghorn W; Bivona TG
Oncogene; 2016 Mar; 35(9):1198-205. PubMed ID: 25982275
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Stamatkin C; Ratermann KL; Overley CW; Black EP
Cancer Biol Ther; 2015; 16(9):1341-52. PubMed ID: 26176612
[TBL] [Abstract][Full Text] [Related]
4. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
5. CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction.
Yeung YT; Fan S; Lu B; Yin S; Yang S; Nie W; Wang M; Zhou L; Li T; Li X; Bode AM; Dong Z
Carcinogenesis; 2020 May; 41(3):377-389. PubMed ID: 31241130
[TBL] [Abstract][Full Text] [Related]
6. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
Karlsson T; Krakstad C; Tangen IL; Hoivik EA; Pollock PM; Salvesen HB; Lewis AE
Oncotarget; 2017 Jan; 8(3):3881-3894. PubMed ID: 28002804
[TBL] [Abstract][Full Text] [Related]
7. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
Park S; Shim JH; Lee B; Cho I; Park WY; Kim Y; Lee SH; Choi Y; Han J; Ahn JS; Ahn MJ; Park K; Sun JM
Lung Cancer; 2019 Aug; 134():7-15. PubMed ID: 31319998
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling.
Du L; Chen X; Cao Y; Lu L; Zhang F; Bornstein S; Li Y; Owens P; Malkoski S; Said S; Jin F; Kulesz-Martin M; Gross N; Wang XJ; Lu SL
Oncogene; 2016 Sep; 35(35):4641-52. PubMed ID: 26876212
[TBL] [Abstract][Full Text] [Related]
9. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
Terashima M; Togashi Y; Sato K; Mizuuchi H; Sakai K; Suda K; Nakamura Y; Banno E; Hayashi H; De Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K
Clin Cancer Res; 2016 Jul; 22(14):3663-71. PubMed ID: 26826182
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
11. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Significance and Mechanism of PI3K p110β Overexpression
in Non-small Cell Lung Cancer].
Xiong Y; Qu L; Li D; Wang Y; Li T
Zhongguo Fei Ai Za Zhi; 2017 Dec; 20(12):808-816. PubMed ID: 29277178
[TBL] [Abstract][Full Text] [Related]
13. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
Li T; Wang J; Wang X; Yang N; Chen SM; Tong LJ; Yang CH; Meng LH; Ding J
J Pharmacol Exp Ther; 2010 Sep; 334(3):830-8. PubMed ID: 20522531
[TBL] [Abstract][Full Text] [Related]
14. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
15. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
[TBL] [Abstract][Full Text] [Related]
17. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
19. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
[TBL] [Abstract][Full Text] [Related]
20. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]